NantKwest – $238 Million IPO

San Diego – August 14, 2015 – Cooley advised the underwriters on NantKwest, Inc.'s $238.3 million initial public offering. NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. The company now trades on The NASDAQ Global Select Market under the symbol "NK."

BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray acted as joint book-running managers for the offering, and MLV & Co. LLC acted as co-manager.

The Cooley corporate securities team advising the underwriters was comprised of partners Charlie Kim and Sean Clayton and associates Kristin VanderPas, Carlos Ramirez, Susan Walker, Adrienne Directo and Sunny Chang.

About Cooley LLP

High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Susan Cooper Philpot Retired Partner, San Francisco
Charlie Kim Partner, San Diego
Sean Clayton Partner, San Diego
Natasha Leskovsek Partner, Washington, DC
Kevin King Partner, Washington, DC
Bill Christiansen Partner, Seattle
Mark Rogel Associate, Seattle
Karen Tsai Associate, Washington, DC
Kristin VanderPas Partner, San Francisco
Phil Mitchell Partner, New York
Carlos Ramirez Associate, San Diego
Adrienne Directo Associate, Los Angeles
Sunny Chang Associate, San Diego